Autocrine motility factor stimulates the invasiveness of malignant cells as well as up-regulation of matrix metalloproteinase-3 expression via a MAPK pathway  by Haga, Arayo et al.
FEBS Letters 582 (2008) 1877–1882Autocrine motility factor stimulates the invasiveness of malignant
cells as well as up-regulation of matrix metalloproteinase-3 expression
via a MAPK pathway
Arayo Hagaa,b,*, Tatsuyoshi Funasakab,c, Yoshihiro Deyashikia, Avraham Razc
a Gifu Prefectural Research Institute for Health and Environmental Science, 1-1, Naka-Fudougaoka, Kakamigahara 504-0838, Japan
b Department of Hygeinics, Gifu Pharmaceutical University, 5-6-1 Mitahora-Higashi, Gifu 502-8585, Japan
c Oncology, Pathology and Radiation Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, School of
Medicine, 110 East Warren, Detroit, MI 48210, USA
Received 26 February 2008; revised 16 April 2008; accepted 6 May 2008
Available online 15 May 2008
Edited by Veli-Pekka LehtoAbstract The autocrine motility factor (AMF) is a multifunc-
tional protein that is involved in tumor progression including
enhanced invasiveness via induction of matrix metalloprotein-
ase-3 (MMP3). The increase in MMP3 was found in an
AMF-high production tumor cell line, and c-Jun, c-Fos and mito-
gen-activated protein kinases (MAPKs) were also highly phos-
phorylated compared with the parent line. AMF stimulation
induced the rapid phosphorylation of the cellular MAPK cascade
and MMP3 secretion, which was blocked using a speciﬁc MAPK
inhibitor. Results of this study suggest that AMF stimulation
stimulates MMP3 expression via a MAPK signaling pathway.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Autocrine motility factor (AMF)/Neuroleukin (NLK)/matu-
ration factor (MF) is an extracellular phospho hexose isomer-
ase (PHI) that is secreted from malignant or neoplastic cells
[1–3]. AMF act in a cytokine-like manner via the autocrine
motility factor receptor (AMFR) 78 kDa glyco protein
(gp78), which is a seven transmembrane glycoprotein [4].
AMF stimulates tumor angiogenesis [5,6], ascite accumulation
[7], apoptotic resistance [8–10], cell proliferation [10,11] and
matrix metalloproteinase-3 (MMP3) secretion [12] as well as
enhanced cell motility. This phenotypic variation is connected
to tumor progression and metastasis. Therefore, understand-
ing the mechanism or the cellular signaling pathway of theseAbbreviations: AMF, autocrine motility factor; AMFR, Autocrine
motility factor receptor; gp78, 78 kDa glyco protein; MMP3, matrix
metalloproteinase-3; MAPK, mitogen-activated protein kinase; JNK,
c-Jun N-terminal kinase; ERK, extracellular signal-regulated kinases;
PKC, protein kinase C; PI3K, phosphatidylinositol 3-kinase; AP-1,
activating protein-1; TRE, TPA response element
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diagnosis.
Activation of the G-protein is recognized in gp78 mediated
cell motil signaling [13,14], and it is reported that protein
kinase A-independent tyrosine kinase and protein kinase C
(PKC) are involved in AMF-induced cell locomotion [15,16].
This vascular progression occurrs via the PKC and phosphati-
dylinositol 3-kinase (PI3K)-related pathway [6]. PKA and
PI3K are also associated with apoptotic resistance via mito-
gen-activated protein kinase (MAPK) [8,10]. Furthermore,
PI3K is involved in cell proliferation via cyclin D1 expression
and cyclin-dependent kinase activity [11]. However, the signal-
ing pathway for MMP3 induction by AMF stimulation is still
unclear.
MMP3 is a member of the matrix metalloproteinases gene
family, which has speciﬁcity for various substrates such as type
IV collagen, laminin, ﬁbronectin, and a variety of other base-
ment proteins [17,18]. Therefore, MMP3 is a key enzyme of tu-
mor invasion and metastasis with destruction of basement
membranes and proteolysis of extracellular matrix.
The promoter region of MMP3 includes a TATA box, TPA
response element (TRE) and an Ets site [19,20]; therefore,
MMP3 is induced by various cytokines and growth factors
such as epidermal growth factor (EGF) [21,22], interleukin-1
(IL-1) and tumor necrosis factor-alpha (TNF-alpha) [23]. It
has ben reported that c-Jun N-terminal kinase (JNK)-medi-
ated phosphorylation of c-Jun is triggered by MMP3 induction
[24–27]. AMF stimulation also induces JNK phosphorylation
via activation of small GTPase Rho [14]. Therefore, it seems
likely that the induction of MMP3 by AMF stimulation may
occur via a JNK cascade, which we demonstrate in this article.2. Materials and methods
2.1. Chemicals and antibodies
JNK inhibitor II and JNK inhibitor II negative control (Merck,
Darmstadt, Germany) were used. All reagents and mediums for cell
culture were purchased from Gibco, Invitrogen (Grand Island, NY).
The recombinant human AMF was puriﬁed by a Glutathione
Sepharose column with PreScission protease (Pharmacia, Uppsala,
Sweden).
Mono-speciﬁc polyclonal antiserum anti-rhAMF [5–8] and anti-
gp78 [2] were used. Anti-rhAMF rabbit IgG was puriﬁed using a Pro-
teinG Sepharose column (Pharmacia). Sheep anti-human MMP3 was
obtained from AbD Serotec (Oxford, UK). Rabbit anti phospho-cJunblished by Elsevier B.V. All rights reserved.
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Santa Cruz, CA), rabbit anti phospho-cFos (T 325) (BioSource Inter-
national Inc., Camarillo, CA), and rabbit anti beta actin (BioLegend,
San Diego, CA) were used. Horseradish peroxidase (HRP)-conjugated
anti-rabbit IgG and anti-sheep IgG antibodies were purchased from
ZYMED Laboratories, Invitrogen (Carlsbad, CA). The human phos-
pho-MAPK Array Kit was obtained from R&D Systems (Minneapo-
lis, MN).
2.2. Cell cultures
Human ﬁbrosarcoma HT-1080 and human acute monocytic leuke-
mia THP-1 cell lines were provided by RIKEN BRC Cell Bank (Tsu-
kuba, Japan). AMF expression vector and mock vector transformed
HT-1080 cells (HT-1080/AMF and HT-1080/vector) [5–8] were used.
These HT-1080 cells were grown in Dulbeccos modiﬁed Eagles med-
ium (DMEM) containing 10% heat-inactivated fetal bovine serum
(FBS) supplemented with non-essential amino acids; cells were har-
vested and passaged for experiments with 0.25% trypsin and 0.025%
EDTA. The THP-1 cells were cultured in RPMI-1640 medium con-
taining 10% FBS. Cultures were maintained at 37 C in an air–5%
CO2 incubator at constant humidity; viability was monitored by try-
pan blue exclusion. To ensure maximal reproducibility, cultures were
grown for no longer than six passages after recovery from frozen
stocks and monitored to prevent mycoplasma contamination.
2.3. Semi-quantitative RT-PCR
Total RNA was prepared by RNA Isolation System (Promega,
Madison, WI) from cultured cells. The cDNA was synthesized by a
reverse transcriptase from total RNA using oligo dT primer of a
ﬁrst-stranded cDNA Synthesis Kit (Takara Co, Osaka, Japan). Then,
the target mRNA was ampliﬁed by PCR with speciﬁc primers
‘‘dAATGCAGAGACGGCGAAGGAG’’ and ‘‘dTGACTCCCCC-
TTTCTCTTCTCGT’’ for human AMF [5–8], ‘‘CGCTTGC-
TGTGTTTTGATGT’’ and ‘‘TCATTGTTGACAGCCAGCTC’’ for
human gp78 [5–8], ‘‘dGGTCACTTCAGAACCTTTCCTG’’ and
‘‘dAGTAACTTCATATGCGGCATCC’’ for human MMP3,
‘‘dTGACGGGGTCACCCACACTGTGCCCATCTA’’, and ‘‘dCTA-
GAAGCATTTGCGGTGGACGATGGAGGG’’ for human beta ac-
tin [5–8]. These primers were designed by Primer3 ver.0.4.0 (http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The PCR condi-
tions were as follows: 94 C for 5 min for initial denaturation, 30 cycles
of 94 C for 30 s, 55 C for 60 s, 72 C for 2 min, and 72 C for 10 min
for ﬁnal extension. PCR products were then subjected to 1.0% agarose
gel electrophoresis.
2.4. Western blotting
The various treated cells (5 · 106) were washed with PBS twice and
lysed by 400 ll of lysis buﬀer [10 mM HEPES pH 7.8, 10 mM KCl,
0.1 mM EDTA, 1 mM DTT, 0.2% Tween 20, protease inhibitor cock-
tail (Complete Mini, Roche Diagnostics, Mannheim, Germany)]. Pro-
tein concentration was measured by Bio-Rad protein Assay Kit (Bio-
Rad Lab., Hercules, CA). Fifteen micrograms of lysate sample was
boiled with 5 · SDS sample buﬀer (50 mM Tris pH8.0, 5 mM EDTA,
5% SDS, 48% glycerol, 1% 2-mercaptoethanol). All samples were sep-
arated by 10% SDS–PAGE and blotted onto PVDF-membranes
(ATTO Co., Tokyo, Japan). The blots were blocked with 5% low-fat
dry milk in PBS containing 0.02% Tween 20 for 1 h at room tempera-
ture. The blocked membrane was incubated with the anti-rhAMF (1/
500), anti-gp78 (1/500), anti MMP3 (1/500), anti phospho-cJun (1/
200), anti phospho-cFos (1/1000), anti-phospho-JNK1 (1/200) and anti
beta actin (1/500) for 1 h, and then with HRP-conjugated anti-rabbit
or anti-sheep (1/2000) secondary antibody for 1 h. The labeled bands
were revealed by 3,3,5,5-tetramethylbenzidine (TMB) staining.
The human phospho-MAPK array analysis was carried out accord-
ing to the manufacturers instructions. The signals were visualized by
TMB staining.
2.5. MMP3 enzymatic activity
Secreted MMP3 was detected by casein zymogram. The conditioned
medium of AMF-treated cells was concentrated to 200-fold by Micro-
con YM-30 centrifugal ﬁlter devices (MILLIPORE, Bedford, MA),
then applied to 10% polyacrylamide gel containing 0.1% casein. Sam-
ples were electrophoresed at 4 C under a non-reducing condition. The
gel was washed with 50 mM Tris pH 7.5, 2% Triton X-100 for 30 mintwice, and 50 mM Tris pH 7.5 for 5 min twice. The washed gel was
incubated at 37 C in 50 mM Tris pH 8.0 containing 150 mM NaCl,
10 mM Ca2+, 1 lM Zn2+ for 16 h. Enzymatic activity was visualized
as negative staining with Coomassie Brilliant Blue.
2.6. Measurement of cell invasiveness
Cell invasiveness was assayed in a Transwell cell culture chamber (24
wells plate) with polyvinylpyrroridone free polycarbonate (PVP) ﬁlters
(pore size: 8 lm) coated with 5 lg of Matrigel (Collaborative Research
Inc., Bedford, MA) on the upper surface. 1 · 105 of cell suspensions
(100 ll) was added to the upper compartment of the Transwell cham-
ber. DMEM (600 ll) was added to the lower compartment and incu-
bated at 37 C in a 5% CO2 atmosphere for 2 h. The PVP ﬁlters
were ﬁxed with methanol and stained with hematoxylin–eosin. The
cells on the upper surface of the ﬁlter were removed by wiping with
a cotton swab. The cells that had invaded the ﬁlters were manually
counted under a microscope at a magniﬁcation of 400.3. Results and discussion
3.1. MMP3 expression and kinase phosphorylation were
enhanced in the AMF-high expression tumor cell line
Two stable transfectant cell clones were isolated [5–8], HT-
1080/vector as a mock cell line and HT-1080/AMF as a human
AMF-high expression line, which had the pBK-CMV expres-
sion vector only and pBK-CMV-human AMF, respectively.
As shown in Fig. 1, the HT-1080 parent line and HT-1080/vec-
tor line were very similar, but the over-expression of AMF was
manifested by its increased mRNA level (Fig. 1A) and cellular
protein (Fig. 1C) in the HT-1080/AMF line. The HT-1080/
AMF line also showed high expression of mRNA (Fig. 1A),
and cellular (Fig. 1C) and extracellular (Fig. 1B) MMP3.
The latent and an active form of MMP3 are recognized in
the extracellular conditioned medium of HT-1080, and pro-
MMP3 level of HT-1080/AMF was high compared with mock
and parent line (Fig. 1B).
Furthermore, phosphorylation of c-Jun and c-Fos of HT-
1080/AMF was much higher compared with the HT-1080 par-
ent line and HT-1080/vector line (Fig. 1C). c-Fos and c-Jun are
components of the transcription factor activating protein-1
(AP-1). It is well known that AP-1 regulates the expression
of various proteins containing MMP3 via a phorbol ester tu-
mor promoter (TPA) response element (TRE) in the promoter
genes. Jun forms homo- and heterodimers, which bind to the
TRE, but Fos is active only as heterodimers with Jun. The
Jun/Fos heterodimers showed a much higher aﬃnity for the
TRE than the Jun homodimer [28–30]. It is likely that the high
pro-MMP3 expression in HT-1080/AMF depends on phos-
phorylation of both c-Jun and c-Fos proteins and they should
compose the active AP-1.
There are three major pathways in the MAPK cascade, and
the Human Phospho-MAPK Array Kit can detect the phos-
phorylation status of extracellular signal-regulated kinases
(ERK1/2), JNK1/2/3, p38 isoforms, Akt (1/2/3), GSK-3 iso-
forms, p70 S6 kinase, etc. The ERK1/2 and JNK1/2/3 of
HT-1080/AMF line was highly phosphorylated compared with
HT-1080/vector line (Fig. 1D), but there were no diﬀerences in
phosphorylation status of other intracellular kinases detected
by the Human Phospho-MAPK Array Kit (data not shown).
ERK1/2 mediates the transcriptional activation of c-Fos by di-
rectly phosphorylating the carboxyl terminal domain of c-Fos
[31,32], and c-Jun is a major substrate of JNK [33,34]. There-
fore, the increased phosphorylation of ERK and JNK
Fig. 1. Comparison of MMP3 expression and MAPK phosphorylation between HT-1080 and variants. (A) RT-PCR analysis of HT-1080 and
variants. The target cDNA of AMF, MMP3 and b-actin were ampliﬁed. Lane 1: HT-1080; lane 2: HT-1080/vector; lane 3: HT-1080/AMF. (B)
Extracellular MMP3 of HT-1080 and variants. Concentrated conditioned medium of each lines were subjected to casein zymogram (lanes 1–3) and
Western analysis (lanes 4–6). Lane 1, 4:HT-1080; lane 2, 5:HT-1080/vector; lane 3, 6:HT-1080 AMF. (C) Western analysis ofHT-1080 and variants.
The AMF, MMP3, phosphorylated c-Jun and c-Fos, and b-actin level of each lysate sample were analyzed by Western method. Lane 1: HT-1080;
lane 2:HT-1080/vector; lane 3:HT-1080 AMF. (D) The human phospho-MAPK array analysis ofHT-1080/vector andHT-1080/AMF. Panel 1:HT-
1080/vector; panel 2: HT-1080/AMF.
A. Haga et al. / FEBS Letters 582 (2008) 1877–1882 1879molecule in the HT-1080/AMF cells does not contradict the
activation of c-Fos/c-Jun and up regulation of pro-MMP3.
3.2. The AMFR is required for over expression of MMP3 by
AMF stimulation
Cell motility stimulation, apoptotic resistance and cell prolif-
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Fig. 2. The gp78 is needed for MMP3 induction by AMF stimulation.
(A) The gp78 expression in HT-1080 and THP-1 cells. The cDNA of
gp78 and b-actin were ampliﬁed from each cell lines (upper), and each
lysate sample was subjected to Western analysis for gp78 and b-actin
(lower). Lane1: HT-1080; lane 2: HT-1080/vector; lane3: HT-1080/
AMF; lane 4: THP-1. (B) Both cell lines were exposed to 0, 1, 5, and
25 ng/ml of puriﬁed AMF for 24 h. Then, the cells and conditioned
medium were subjected to RT-PCR (upper), Western analysis
(medium) and casein zymogram (lower) for MMP3 detection. Lanes
1–4; THP-1; lanes 5–8: HT-1080. Lanes 1, 5: control (0 ng/ml); lanes 2,
6: 1 ng/ml AMF; lanes 3, 7: 5 ng/ml AMF; lane 4, 8: 25 ng/ml AMF.gp78, which is a gp78 present on the cell surface. gp78 was
identiﬁed as a sialylated peanut agglutinin binding fraction
of malignant cell membranes [35,36], and its expression level
was found to be increased in a number of diﬀerent malignan-
cies, correlating with the metastatic potential [37–39]. The
binding between AMF and gp78 occurs via a side chain of
gp78 [40], and Rho activation signaling connects JNK phos-
phorylation [14].
We have previously described that some leukemic cell lines
do not express gp78 [41]. The human acute monocytic leuke-
mia THP-1 line also showed reduced gp78 mRNA and protein
levels (Fig. 2A). This THP-1 line did not respond to AMF
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Fig. 3. Time course activation of signaling molecules of HT-1080 cell
line and induction of MMP3 after AMF stimulation. The HT-1080
cells were stimulated by 25 ng/ml of AMF for 0, 10, 30, 60, 180, and
360 min, then subjected to RT-PCR for MMP3 mRNA, Western
analysis for phosphorylation status of signaling molecules and MMP3
expression, and casein zymogram for extracellular MMP3. Lane 1:
0 min; lane 2: 10 min; lane 3: 30 min; lane 4: 60 min; lane 5: 180 min;
lane 6: 360 min.
1880 A. Haga et al. / FEBS Letters 582 (2008) 1877–1882altered by AMF exposure (Fig. 2B, lanes 1–4), whereas obvi-
ous over-expression of MMP3 was recognized in the HT-
1080 line exposed to 25 ng/ml AMF (Fig. 2B, lane 8). These
data suggest that the pro-MMP3 up-regulation by AMF stim-
ulation also required gp78.
3.3. Time-dependent activation of signaling molecule and
MMP3 expression
JNK, c-Fos and c-Jun were clearly phosphorylated in the
HT-1080/AMF line. Therefore, the phosphorylation status of
this intracellular signaling molecule was investigated using
the HT-1080 parent line. The cells were stimulated by 25 ng/
ml of AMF for 0, 10, 30, 60, 180, and 360 min, then subjected
to each experiment.
As shown in Fig. 3, activation of the signaling molecule is
recognized at an early stage. Clearly, phosphorylation of
JNK1 was observed at 10 min after stimulation, and phos-
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Fig. 4. Pre-treatment by JNK inhibitor exhibits the induction of
MMP3 on HT-1080 cells. The HT-1080 line was exposed to 0, 50, 100,
and 200 nM of JNK inhibitor and 200 nM of JNK inhibitor negative
control for 6 h. Then, the treated cells were stimulated by 25 ng/ml of
AMF for 6 h, and subjected to RT-PCR for MMP3 mRNA and
Western analysis for phosphorylation status of c-Jun and MMP3
expression. Lane 1: control (without AMF addition); lane 2: +25 ng/ml
AMF; lane 3: +50 nM inhibitor with AMF; lane 4: +100 nM inhibitor
with AMF; lane 5: +200 nM inhibitor with AMF; lane 6: +200 nM
inhibitor negative control with AMF.




Fig. 5. Anti-AMF IgG exhibits the MMP3 secretion and cell invasiveness. (A
medium containing 0, 100, 500, and 1000 ng/ml anti AMF IgG was added, an
MMP3 mRNA and casein zymogram for extracellular MMP3. Lane 1: HT-
HT-1080/AMF +100 ng/ml IgG; lane 4: HT-1080/AMF +500 ng/ml IgG; la
variants. HT-1080 (1 · 105) cells and variant lines were treated with 1000 ng
Column 1: HT-1080; column 2: HT-1080 mock; column 3: HT-1080 AMF.30 min. The over-expression of MMP3 mRNA occurred at
60 min, and an increase in cellular and extracellular pro-
MMP3 was observed at 180 min. This activation of signaling
molecules was matched with stimulation by EGF [21,22],
IL-1 and TNF-alpha [23].
3.4. MMP3 induction by AMF stimulation is depended on JNK
pathway
Anthra [1,9-cd] pyrazol-6 (2H)-one; 1,9-pyrazoloanthrone
(JNK inhibitor II) is a speciﬁc inhibitor for the JNK family.
The IC50 is 0.04 lM for JNK1/2, and 0.09 lM for JNK3.
N1-Methyl-1,9-pyrazoloanthrone (JNK inhibitor negative
control) is a negative control for JNK inhibitor. The IC50 is
18 lM for JNK1/2, and 24 lM for JNK3 [42,43].
The HT-1080 parent line was exposed to 0, 50, 100, and
200 nM of JNK inhibitor and 200 nM of JNK inhibitor nega-
tive control for 6 h. Then, the treated cells were stimulated by
25 ng/ml of AMF for 6 h, and subjected to each analysis.
As shown in Fig. 4, mRNA expression and protein induction
of MMP3 by AMF stimulation was clearly exhibited by treat-
ment with JNK inhibitor II (Fig. 4, lanes 3–5), whereas JNK
inhibitor negative control did not aﬀect for pro-MMP3 pro-
duction (Fig. 4, lane 6). JNK inhibitor II also impaired the
phosphorylation of c-Jun. These data strongly suggest that
the conventional JNK signaling pathway mediates the up-reg-
ulation of MMP3 by AMF stimulation. The AMF-induced
JNK activation is also connected to the enhancement of cell
motility via phosphorylation of myosin light chain kinase
[14]. The MAPK pathway has a signiﬁcant role in regulating
the expression of various genes including MMP7 [44],
MMP9 [45], MMP13 [46]. Therefore, further studies are
needed to investigate the eﬀect of AMF stimulation on regula-
tion of these molecules.
3.5. Anti-AMF treatment can regulate MMP3 induction
We have previously established that the anti human AMF
polyclonal IgG can exhibit AMF activity, including cell motil-
ity [5], angiogenesis [5], hyperpermeability of ascite ﬂuid [7]
and apoptotic resistance [8]. Therefore, we investigated the ef-
fect of antibody against MMP3 induction.
Cultured HT-1080/AMF cells were washed with PBS twice



















) Cultured HT-1080/AMF cells were washed with PBS twice and fresh
d cells were cultured for a further 24 h, then subjected to RT-PCR for
1080/vector, without IgG; lane 2: HT-1080/AMF, without IgG; lane 3:
ne 5: HT-1080/AMF +1 lg/ml IgG. (B) Invasiveness of HT-1080 and
/ml anti AMF IgG for 24 hr and were applied to the invasion assay.
*P < 0.01 by t-test.
A. Haga et al. / FEBS Letters 582 (2008) 1877–1882 1881control) anti AMF IgG was added, and cells were cultured for
a further 24 h, then subjected to each experiment. As shown in
Fig. 5A, mRNA expression and enzymatic activity of MMP3
was decreased by treatment with a high antibody concentra-
tion.
HT-1080 (1 · 105) cells and variant lines were treated with
1 lg/ml anti AMF IgG for 24 h and were applied to the inva-
sion assay. A clear reduction of invasiveness on HT-1080 par-
ent and HT-1080/vector lines with anti AMF IgG treatment
was not observed, but signiﬁcant inhibition was observed with
the IgG treatedHT-1080/AMF line (Fig. 5B). Cell invasion is a
complicated phenomenon that includes several steps including
adhesion to the basement membrane, enzymatic breakdown of
the matrix and migration to the extracellular space. Excess
AMF enhances protease activity and cell motility; therefore,
neutralization of AMF might be eﬀective for ﬁxing the HT-
1080/AMF line.
The AMF high expression variant line HT-1080/AMF is an
example of tumor progression, and it shows various malignant
phenotypes including MMP3 upregulation. Therefore, target-
ing the AMF of malignant cancer by using antibodies or
chemicals [1,5,47,48] should eﬀectively support cancer treat-
ment.
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